The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Open accessAbstract
BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition. METHODS: In this randomized, open-label, phase 3 trial, we assigned, in a 2:1 ratio, 361 patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within 6 months after platinum-based chemotherapy to receive nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks or standard, single-agent systemic therapy (methotrexate, docetaxel, or cetuximab). The primary end point was overall survival. Additional end points included progression-free survival, rate of objective response, safety, and patient-reported quality of life. RESULTS: The median overall survival was 7.5 months (95% confidence interval [CI], 5.5 to 9.1) in the nivolumab group versus 5.1 months (95% CI, 4.0 to 6.0) in the group that received standard therapy. Overall survival was significantly longer with nivolumab than with standard therapy (hazard ratio for death, 0.70; 97.73% CI, 0.51 to 0.96; P=0.01), and the estimates of the 1-year survival rate were approximately 19 percentage points higher with nivolumab than with standard therapy (36.0% vs. 16.6%). The median progression-free survival was 2.0 months (95% CI, 1.9 to 2.1) with nivolumab versus 2.3 months (95% CI, 1.9 to 3.1) with standard therapy (hazard ratio for disease progression or death, 0.89; 95% CI, 0.70 to 1.13; P=0.32). The rate of progression-free survival at 6 months was 19.7% with nivolumab versus 9.9% with standard therapy. The response rate was 13.3% in the nivolumab group versus 5.8% in the standard-therapy group. Treatment-related adverse events of grade 3 or 4 occurred in 13.1% of the patients in the nivolumab group versus 35.1% of those in the standard-therapy group. Physical, role, and social functioning was stable in the nivolumab group, whereas it was meaningfully worse in the standard-therapy group. CONCLUSIONS: Among patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, treatment with nivolumab resulted in longer overall survival than treatment with standard, single-agent therapy. (Funded by Bristol-Myers Squibb; CheckMate 141 ClinicalTrials.gov number, NCT02105636 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although PD-L1 expression on tumor cells was correlated with treatment efficacy in melanoma patients (67, 108), it was not in patients with squamous cell carcinoma, non-small cell lung cancer and Merkel cell carcinoma (70, 72, 74).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [70]
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Survival Analysis Techniques for Censored and Truncated Data
Rao, M. B., Klein, J. P., & Moeschberger, M. L. (1998) · Technometrics · doi:10.2307/1270658 · Cited by 3,617
Survival analysis using sas®: a practical guide
Allison, P. D. (1995) · International Linear Collider · Cited by 3,570
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Cooper, J. S., Pajak, T. F., Forastiere, A. A., Jacobs, J., Campbell, B. H., Saxman, S. B., Kish, J. A., Kim, H. E., Cmelak, A. J., Rotman, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032646 · Cited by 3,271
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,010
Yu, X., Long, Y., Chen, B., Tong, Y., Shan, M., Jia, X., Hu, C., Liu, M., Zhou, J. Y., Tang, F., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004590 · Cited by 73
Liu, Z., Meng, X., Tang, X., Zou, W., & He, Y. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03310-5 · Cited by 75
Diversity of immune checkpoints in cancer immunotherapy
Guo, Z., Zhang, R., Yang, A., & Zheng, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121285 · Cited by 73
Gjuka, D., Adib, E., Garrison, K., Chen, J., Zhang, Y., Li, W., Boutz, D. R., Lamb, C., Tanno, Y., Nassar, A. H., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.09.005 · Cited by 75
Emerging therapies for breast cancer
Hu, X., Huang, W., & Fan, M. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0466-3 · Cited by 71
Current studies of immunotherapy in head and neck cancer
Dogan, V., Rieckmann, T., Münscher, A., & Busch, C. (2018) · Clinical Otolaryngology · doi:10.1111/coa.12895 · Cited by 63
Excellent response to chemotherapy post immunotherapy
Dwary, A. D., Master, S. R., Patel, A., Cole, C., Mansour, R. P., Mills, G. M., Koshy, N. V., Peddi, P., Burton, G. V., Hammoud, D. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20030 · Cited by 66
Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy
Rivadeneira, D. B., & Delgoffe, G. M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0894 · Cited by 69
New Therapies in Head and Neck Cancer
Santuray, R. T., Johnson, D. E., & Grandis, J. R. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.03.006 · Cited by 67
Park, J., Kwon, M., Kim, K. H., Kim, T.-S., Hong, S.-H., Kim, C. G., Kang, S., Moon, J. H., Kim, E. H., Park, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2564 · Cited by 68
Immune checkpoint inhibitors in the treatment of virus-associated cancers
Gao, P., Lazare, C., Cao, C., Meng, Y., Wu, P., Zhi, W., Lin, S., Wei, J.-C., Huang, X., Xi, L., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0743-4 · Cited by 57
Zhang, N., Tu, J., Wang, X., & Chu, Q. (2019) · Immunotherapy · doi:10.2217/imt-2018-0110 · Cited by 65
Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1
Pan, Y., Fei, Q., Xiong, P., Yang, J., Zhang, Z., Lin, X., Pan, M., Lu, F., & Huang, H. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1581529 · Cited by 66
Amodio, V., Mauri, G., Reilly, N. M., Bianchi, A. S., Siena, S., Bardelli, A., & Germano, G. (2021) · Cancers · doi:10.3390/cancers13112638 · Cited by 67
Mito, I., Takahashi, H., Kawabata‐Iwakawa, R., Ida, S., Tada, H., & Chikamatsu, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-95718-9 · Cited by 66
Hu, Z., Wen, Y., Ma, R., Chen, L., Zeng, X., Wen, W., & Sun, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.727762 · Cited by 65
Foy, J.-P., Karabajakian, A., Ortiz-Cuàran, S., Boussageon, M., Michon, L., Bouaoud, J., Fekiri, D., Robert, M., Baffert, K.-A., Herve, G., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.034 · Cited by 53
Self-citationPD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
Huang, C., Ren, S., Chen, Y., Liu, A., Wu, Q., Jiang, T., Lv, P., Song, D., Hu, F., Lan, J., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade4186 · Cited by 67
Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors
Pawłowska, A., Rekowska, A. K., Kuryło, W., Pańczyszyn, A., Kotarski, J., & Wertel, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310859 · Cited by 71
Nivolumab for Patients With High-Risk Oral Leukoplakia
Hanna, G. J., Villa, A., Nandi, S. P., Shi, R., O’Neill, A., Liu, M., Quinn, C. T., Treister, N. S., Sroussi, H., Vacharotayangul, P., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.4853 · Cited by 66
Self-citationMell, L. K., Torres‐Saavedra, P. A., Wong, S. J., Kish, J. A., Chang, S. S., Jordan, R. C., Liu, T., Truong, M. T., Winquist, E. W., Takiar, V., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00507-2 · Cited by 67
Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment
Rothenberger, N. J., & Stabile, L. P. (2017) · Cancers · doi:10.3390/cancers9040039 · Cited by 66
Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade
Kaunitz, G. J., Loss, M. J., Rizvi, H. A., Ravi, S., Cuda, J. D., Bleich, K. B., Esandrio, J., Sander, I. B., Le, D. T., Diaz, L. A., et al. (2017) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000900 · Cited by 66
Wen, Y., Lin, H., Li, H., Zhao, Y., Lui, V. W. Y., Chen, L., Wu, X., Sun, W., & Wen, W. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2265-2 · Cited by 66
Chen, H., Yang, M., Wang, Q., Song, F., Li, X., & Chen, K. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1608132 · Cited by 66
Baxi, V., Lee, G., Duan, C., Pandya, D., Cohen, D. N., Edwards, R., Chang, H., Li, J., Elliott, H., Pokkalla, H., et al. (2022) · Modern Pathology · doi:10.1038/s41379-022-01119-2 · Cited by 66
Chen, R.-Y., Lin, Y., Shen, W.-C., Hsieh, T., Yen, K., Chen, S.-W., & Kao, C. (2018) · Scientific Reports · doi:10.1038/s41598-017-18489-2 · Cited by 63
Kao, H., & Lou, P. (2019) · Head & Neck · doi:10.1002/hed.25930 · Cited by 66
Cellular Signaling Pathways in Medium and Large Vessel Vasculitis
Watanabe, R., Berry, G. J., Liang, D. H., Goronzy, J. J., & Weyand, C. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.587089 · Cited by 65
Pierik, A. S., Leemans, C. R., & Brakenhoff, R. H. (2021) · Cancers · doi:10.3390/cancers13112635 · Cited by 64
Bourhis, J., Auperin, A., Borel, C., Lefebvre, G., Racadot, S., Geoffrois, L., Sun, X., Saâda-Bouzid, E., Cirauqui, B., Rutkowski, T., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01850-1 · Cited by 66
Self-citationImmunotherapy in colorectal cancer: for the select few or all?
Arora, S. P., & Mahalingam, D. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.06.10 · Cited by 66
Brand, F. Z. A., Suter, N., Adam, J., Faulques, B., Maietta, A., Soulières, D., & Blais, N. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0332-z · Cited by 64
The Use of Microfluidic Technology for Cancer Applications and Liquid Biopsy
Kulasinghe, A., Wu, H., Punyadeera, C., & Warkiani, M. E. (2018) · Micromachines · doi:10.3390/mi9080397 · Cited by 67
Galot, R., Tourneau, C. L., Guigay, J., Licitra, L. F., Tinhofer, I., Kong, A. H., Caballero, C. A., Fortpied, C., Bogaerts, J., Govaerts, A.-S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy452 · Cited by 67
Self-citationClinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma
Gougis, P., Moreau-Bachelard, C., Kamal, M. T., Gan, H. K., Borcoman, É., Torossian, N., Bièche, I., & Tourneau, C. L. (2019) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkz055 · Cited by 63
Clinical and immune profiling for cancer of unknown primary site
Haratani, K., Hayashi, H., Takahama, T., Nakamura, Y., Tomida, S., Yoshida, T., Chiba, Y., Sawada, T., Sakai, K., Fujita, Y., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0720-z · Cited by 64
Immune gene expression in head and neck squamous cell carcinoma patients.
Lecerf, C., Kamal, M., Vacher, S., Chemlali, W., Schnitzler, A., Morel, C., Dubot, C., Jeannot, E., Meseure, D., Klijanienko, J., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.08.028 · Cited by 63
Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma
Adhikaree, J., Moreno-Vicente, J., Kaur, A. P., Jackson, A. M., & Patel, P. M. (2020) · Cells · doi:10.3390/cells9020263 · Cited by 68
Immune-related gene signature for predicting the prognosis of head and neck squamous cell carcinoma
She, Y., Kong, X., Ge, Y.-P., Yin, P., Liu, Z.-Y., Chen, J.-Y., Gao, F., & Fang, S.-L. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1104-7 · Cited by 63
Ye, J., Ji, X., Dennis, P. A., Abdullah, H. A., & Mukhopadhyay, P. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1956 · Cited by 69
Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy
Boone, C. E., Wang, L., Gautam, A., Newton, I. G., & Steinmetz, N. F. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1739 · Cited by 66
Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives
Roviello, G., Catalano, M., Santi, R., Palmieri, V. E., Vannini, G., Galli, I. C., Buttitta, E., Villari, D., Rossi, V., & Nesi, G. (2021) · Cancers · doi:10.3390/cancers13174411 · Cited by 66
Luginbuhl, A., Johnson, J. M., Harshyne, L. A., Linnenbach, A. J., Shukla, S. K., Alnemri, A. E., Kumar, G., Cognetti, D. M., Curry, J., Kotlov, N., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1816 · Cited by 66
Wang, D.-K., Fang, J., Wen, S., Li, Q., Wang, J., Yang, L., Dai, W., Lu, H., Guo, J., Shan, Z., et al. (2022) · International Journal of Oral Science · doi:10.1038/s41368-022-00160-w · Cited by 67
Image-guided intratumoral immunotherapy: Developing a clinically practical technology
Som, A., Rosenboom, J., Chandler, A., Sheth, R. A., & Wehrenberg-Klee, E. P. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114505 · Cited by 63
Patil, N. S., Righi, L., Koeppen, H., Zou, W., Izzo, S., Grosso, F., Libener, R., Iacono, M. L., Monica, V., Buttigliero, C., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.09.1968 · Cited by 64
Felice, F. D., Polimeni, A., Valentini, V., Brugnoletti, O., Cassoni, A., Greco, A., VINCENTIIS, M. D., & Tombolini, V. (2018) · Neoplasia · doi:10.1016/j.neo.2018.01.002 · Cited by 64
Lu, S., Concha‐Benavente, F., Shayan, G., Srivastava, R. M., Gibson, S. P., Wang, L., Gooding, W. E., & Ferris, R. L. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.01.019 · Cited by 65
Self-citationMorihiro, T., Kuroda, S., Kanaya, N., Kakiuchi, Y., Kubota, T., Aoyama, K., Tanaka, T., Kikuchi, S., Nagasaka, T., Nishizaki, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41177-2 · Cited by 64
Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance
Chen, S.-W., Li, S.-M., Shi, D., Jiang, W.-M., Song, M., Yang, A., Li, Y.-D., Bei, J.-X., Chen, W.-K., & Zhang, Q. (2019) · International Journal of Biological Markers · doi:10.1177/1724600819884722 · Cited by 64
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
Charap, A., Enokida, T., Brody, R., Sfakianos, J. P., Miles, B. A., Bhardwaj, N., & Horowitz, A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001523 · Cited by 66
Cell Fate Reprogramming in the Era of Cancer Immunotherapy
Zimmermannova, O., Caiado, I., Ferreira, A. G., & Pereira, C.-F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714822 · Cited by 56
Tringale, K. R., Carroll, K. T., Zakeri, K., Sacco, A. G., Barnachea, L., & Murphy, J. D. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx226 · Cited by 63
Powell, S. F., Mazurczak, M. A., Dib, E. G., Bleeker, J. S., Geeraerts, L., Tinguely, M., Lohr, M. M., McGraw, S. C., Jensen, A. W., Ellison, C. A., et al. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01235-5 · Cited by 63
Gao, L., Yang, F., Tang, D., Xu, Z., Tang, Y., Yang, D., Sun, D., Chen, Z., & Teng, Y. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02574-0 · Cited by 68
Economopoulou, P., Kotsantis, I., & Psyrri, A. K. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000122 · Cited by 63
Fallon, J. K., Vandeveer, A. J., Schlom, J., & Greiner, J. W. (2017) · Oncotarget · doi:10.18632/oncotarget.16137 · Cited by 64
Martini, D. J., Hamieh, L., McKay, R. R., Harshman, L. C., Moreira, R. B., Norton, C. K., Steinharter, J. A., Krajewski, K. M., Gao, X. Y., Schutz, F. A., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0220 · Cited by 63
Isolation of Tumor-Infiltrating Lymphocytes by Ficoll-Paque Density Gradient Centrifugation
Tan, Y. S., & Lei, Y. L. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9167-9_8 · Cited by 63
Bossi, P., Alfieri, S., Strojan, P., Takes, R. P., López, F., Mäkitie, A. A., Saba, N. F., Rodrigo, J. P., Bradford, C. R., Suarez, C. M., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.01.018 · Cited by 63
Self-citationBahig, H., Ye, R. Z., Aubin, F., Nguyen‐Tan, P. F., Soulières, D., Debenham, B. J., Charpentier, D., Palma, D. A., Chua, N. S., Winquist, E., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2026.07.052 · Cited by 62
Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers
Pagni, F., Guerini‐Rocco, E., Schultheis, A. M., Grazia, G., Rijavec, E., Ghidini, M., Lopez, G., Venetis, K., Croci, G. A., Malapelle, U., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215452 · Cited by 61
Xie, F., Zhang, J. J., Wang, J., Reuben, A., Xu, W., Yi, X., Varn, F. S., Ye, Y., Cheng, J., Yu, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1744 · Cited by 61
A review on the advances and challenges of immunotherapy for head and neck cancer
Cheng, G., Dong, H., Yang, C., Yang, L., Wu, Y., Zhu, L., Tong, X., & Wang, S. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02024-5 · Cited by 64
Small extracellular vesicle PD-L1 in cancer: the knowns and unknowns
Yu, Z., Liu, J., & Chen, G. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00287-3 · Cited by 64
Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas
Li, Y., Goldberg, E. M., Chen, X., Xu, X., McGuire, J. T., Leuzzi, G., Karagiannis, D., Tate, T., Farhangdoost, N., Horth, C., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.09.007 · Cited by 65
Kang, J. J., Yu, Y., Chen, L., Zakeri, K., Gelblum, D. Y., McBride, S. M., Riaz, N., Tsai, C. J., Kriplani, A., Hung, T. K. W., et al. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21758 · Cited by 63
Advancements of radiotherapy for recurrent head and neck cancer in modern era
Zhang, S., Zeng, N., Yang, J., He, J., Zhu, F., Liao, W., Xiong, M., & Li, Y. (2023) · Radiation Oncology · doi:10.1186/s13014-023-02342-0 · Cited by 62
Characterization of KIF11 as a novel prognostic biomarker and therapeutic target for oral cancer
Daigo, K., Takano, A., Thang, P. M., Yoshitake, Y., Shinohara, M., Tohnai, I., Murakami, Y., Maegawa, J., & Daigo, Y. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4181 · Cited by 62
Owen, D. H., Chu, B. F., Lehman, A. M., Annamalai, L., Yearley, J. H., Shilo, K., & Otterson, G. A. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.013 · Cited by 64
Patient performance status and cancer immunotherapy efficacy: a meta-analysis
Bersanelli, M., Brighenti, M., Buti, S., Barni, S., & Petrelli, F. (2018) · Medical Oncology · doi:10.1007/s12032-018-1194-4 · Cited by 64
HPV-Associated Anal Cancer in the HIV/AIDS Patient
Wang, C.-C. J., & Palefsky, J. M. (2018) · Cancer treatment and research · doi:10.1007/978-3-030-03502-0_7 · Cited by 63
Lenouvel, D., González‐Moles, M. Á., Talbaoui, A., Ramos‐García, P., González‐Ruiz, L., Ruiz‐Ávila, I., & Montoya, J. A. G. (2019) · Oral Diseases · doi:10.1111/odi.13088 · Cited by 62
Sun, N.-Y., Chen, Y., Wu, W., Lin, H.-W., Chiang, Y., Chang, C.-F., Tai, Y., Hsu, H., Chen, C., Sun, W., et al. (2019) · Cancers · doi:10.3390/cancers11091400 · Cited by 65
Cancer immunotherapy: the art of targeting the tumor immune microenvironment
da Silva, J. L., dos Santos, A. L. S., Nunes, N. C. C., da Silva, F. D. M. L., Ferreira, C. G., & de Melo, A. C. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03894-3 · Cited by 62
Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition
Pan, P., & Haggiagi, A. M. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0859-2 · Cited by 66
Machiels, J.-P., Leemans, C. R., Golusiński, W., Grau, C., Licitra, L. F., & Grégoire, V. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105042 · Cited by 61
Self-citationAdvanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy
Cremolini, C., Vitale, E., Rastaldo, R., & Giachino, C. (2021) · Nanomaterials · doi:10.3390/nano11030661 · Cited by 64
Radiomic biomarkers of tumor immune biology and immunotherapy response
Wang, J. H., Wahid, K. A., van Dijk, L. V., Farahani, K., Thompson, R. F., & Fuller, C. D. (2021) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2021.03.006 · Cited by 61
Wang, F., Wu, L., Yin, L., Shi, H. M., Gu, Y., & Xing, N. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.901 · Cited by 60
Osman, A. A., Arslan, E., Bartels, M. D., Michikawa, C., Lindemann, A., Tomczak, K. J., Yu, W., Sandulache, V. C., Ma, W., Shen, L., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2747 · Cited by 63
Harrington, K. J., Champiat, S., Brody, J., Cho, B. C., Romano, E., Golan, T., Hyngstrom, J. R., Strauss, J. F., Oh, D. Y., Popovtzer, A., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3630 · Cited by 61
Self-citationBorcherding, N. C., Kolb, R. H., Gullicksrud, J. A., Vikas, P., Zhu, Y., & Zhang, W. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.030 · Cited by 60
Xiao, R., Allen, C. T., Tran, L. B., Patel, P., Park, S. J., Chen, Z., Waes, C. V., & Schmitt, N. C. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1471440 · Cited by 62
Pestana, R. C., Becnel, M., Rubin, M. L., Torman, D., Crespo, J., Phan, J., Hanna, E. Y., Bell, D., Glisson, B. S., Johnson, J. M., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104523 · Cited by 61
Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis
Pasquali, S., Chiarion‐Sileni, V., Rossi, C. R., & D, S. M. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.006 · Cited by 60
Solinas, C., Porcu, M., Hlavatá, Z., Silva, P. D., Puzzoni, M., Willard-Gallo, K., Scartozzi, M., & Saba, L. (2017) · Critical reviews in oncology/hematology · doi:10.1016/j.critrevonc.2017.09.017 · Cited by 57
Pembrolizumab for the treatment of cervical cancer
Marret, G., Borcoman, É., & Tourneau, C. L. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1646721 · Cited by 60
Camelliti, S., Noci, V. L., Bianchi, F., Moscheni, C., Arnaboldi, F., Gagliano, N., Balsari, A., Garassino, M. C., Tagliabue, E., Sfondrini, L., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01721-9 · Cited by 61
Botticelli, A., Zizzari, I. G., Scagnoli, S., Pomati, G., Strigari, L., Cirillo, A., Cerbelli, B., Filippo, A. D., Napoletano, C., Scirocchi, F., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11070651 · Cited by 60
Takenaka, Y., Oya, R., Takemoto, N., & Inohara, H. (2022) · Head & Neck · doi:10.1002/hed.26997 · Cited by 64
PD-L1 Expression in Pancreatic Cancer
Zheng, L. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw304 · Cited by 59
Mechanisms of DNA damage repair in adult stem cells and implications for cancer formation
Weeden, C. E., & Asselin-Labat, M.-L. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.10.015 · Cited by 61
Franzen, A., Vogt, T. J., Müller, T., Dietrich, J., Schröck, A., Golletz, C., Brossart, P., Bootz, F., Landsberg, J., Kristiansen, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23080 · Cited by 60
Lin, A. J., Gang, M., Rao, Y. J., Campian, J. L., Daly, M. D., Gay, H. A., Oppelt, P., Jackson, R. S., Rich, J. T., Paniello, R. C., et al. (2019) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2019.0034 · Cited by 60
Guo, Y., Ahn, M., Chan, A. T. �., Wang, C.-H., Kang, J. H., Kim, S.-B., Bello, M. D. G., Arora, R. S., Zhang, Q., He, X., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz388 · Cited by 60
Mutational spectrum of tobacco associated oral squamous carcinoma and its therapeutic significance
Batta, N., & Pandey, M. (2019) · World Journal of Surgical Oncology · doi:10.1186/s12957-019-1741-2 · Cited by 60
Molecular Therapeutics in Development for Epidermolysis Bullosa: Update 2020
Has, C., South, A. P., & Uitto, J. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00466-7 · Cited by 64
Chung, C. H., Bonomi, M. R., Steuer, C. E., Li, J., Bhateja, P., Johnson, M., Masannat, J., Song, F., Hernandez-Prera, J. C., Wenig, B. M., et al. (2021) · Cancers · doi:10.3390/cancers13051180 · Cited by 58
Self-citation
Metadata
- Authors
- Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Iglesias Docampo, L. C., Haddad, R., Rordorf, T., Kiyota, N., Tahara, M., Monga, M., Lynch, M., Geese, W. J., Kopit, J., Shaw, J. W., & Gillison, M. L.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-10
- Volume
- 375
- Issue
- 19
- Pages
- 1856-1867
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5564292
- OpenAlex
- W2529484692
- Cited by
- 5,101
- References
- 26
- Citations by year
- 2026: 358 · 2025: 461 · 2024: 500 · 2023: 490 · 2022: 574 · 2021: 687 · 2020: 617 · 2019: 543 · 2018: 486 · 2017: 358 · 2016: 17
- FWCI
- 452.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- Bristol-Myers Squibb
- National Institute for Health and Care Research (NF-SI-0515-10101)
- Ono Pharmaceutical
- National Cancer Institute (P50CA097190, R01CA206517)
- Topics
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
- Keywords
- nivolumab, PD-1 inhibitors, immune checkpoint inhibitors, platinum-refractory disease, overall survival, progression-free survival, objective response rate, quality of life, treatment-related adverse events, cetuximab, docetaxel, methotrexate, single-agent chemotherapy, metastatic head and neck cancer, immunotherapy
- MeSH terms
- Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Squamous Cell, Female, Head and Neck Neoplasms, Humans, Male, Neoplasm Recurrence, Local, Quality of Life, Survival Analysis, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
